BionTech Covid-19 Vaccine | Page 2 | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
May 31, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, MAY 31, 2025

BionTech Covid-19 Vaccine

"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin, chief executive of the company.  Photo: Collected
Coronavirus chronicle

China likely to approve BioNTech's Covid-19 vaccine by July - WSJ

If approved, it would become the first foreign Covid-19 vaccine to be authorised in the country

Unilever gets vaccine partnership offers as it plots worker safety strategy
Coronavirus chronicle

Unilever gets vaccine partnership offers as it plots worker safety strategy

"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin, chief executive of the company.  Photo: Collected
Coronavirus chronicle

BioNTech aims for 2 billion Covid-19 vaccine doses in 2021

"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin, chief executive of the company.  Photo: Collected
Coronavirus chronicle

BioNTech founders warn of vaccine supply gaps

"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin, chief executive of the company.  Photo: Collected
Coronavirus chronicle

China's Fosun plans plant to make BioNTech's Covid-19 vaccine -Caixin

Pharmacist Susanne Wohlgemuth prepares Pfizer/BioNTech Covid-19 vaccinations at the Haus an der Linde nursing home in Lichtentanne, Saxony, Germany December 27, 2020, the day when the country starts its vaccination programme. Hendrik Schmidt/Pool via Reuters
Coronavirus chronicle

EU starts mass vaccination in 'touching moment of unity'

Mutated Covid-19 variant could make herd immunity more difficult: BioNTech boss
World+Biz

Mutated Covid-19 variant could make herd immunity more difficult: BioNTech boss

Photo: Collected.
Coronavirus chronicle

UK approves Pfizer-BioNTech vaccine for use

The question arises whether a member state would want to administer to its citizens a vaccine that has not been reviewed by EMA

Photo: Collected
Coronavirus chronicle

Covid-19 vaccine: The next steps

A man wearing a protective face mask walks past the logo of Sanofi at the company's headquarters in Paris, France, April 24, 2020/ Reuters
Coronavirus chronicle

Sanofi says its vaccine won’t need supercooling

Ugur Sahin, CEO and co-founder of German biotech firm BioNTech, is interviewed by journalists in Marburg, Germany September 17, 2020. REUTERSFabian BimmerFile Photo
Coronavirus chronicle

Vaccine scientist hopes for return to ‘normal’ by next winter

Ugur Sahin, CEO and co-founder of German biotech firm BioNTech. Picture: Reuters
Coronavirus chronicle

Covid-19: BioNTech CEO says normal life by next winter

A worker passes a line of freezers holding coronavirus disease (Covid-19) vaccine candidate BNT162b2 at a Pfizer facility in Puurs, Belgium in an undated photograph. Pfizer/Handout via REUTERS
Global Economy

Vaccine is inexact bonus for freight and freezers

  • Show More
  • loading...
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net